🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Clinical Trials in the Netherlands / NCT04852198
Recruiting Not applicable

Comparing 150cm OAGB With 150cm Biliopancreatic Limb RYGB. A Non-inferiority Trial

NCT04852198 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Flevoziekenhuis
Phase
Not applicable
Started
2021-12-13
Last updated
2024-04-23

Condition(s) studied

Bariatric Surgery CandidateObesityObesity, Morbid

Investigational drug(s) / intervention(s)

OAGBRYGB

OAGB: Simplified gastric bypass procedure

RYGB: Roux-en-Y gastric bypass. Standard procedure in the Netherlands

Study summary

The purpose of this study is to assess the safety and efficiency of OAGB compared to RYGB

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * body-mass index (BMI) of 40 kg/m2 or higher, or 35 kg/m2 or higher with the presence of at least one comorbidity (type 2 diabetes, high blood pressure, obstructive sleep apnoea, dyslipidaemia, osteoarthritis of the hip or knee) * a positive evaluation by our BMDT Exclusion Criteria: * Presence of H. Pylori, resistant to eradication therapy * chronic diarrhoea * history of previous bariatric or extensive abdominal surgery

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Flevoziekenhuis Almere Stad Netherlands Recruiting
OLVG Amsterdam Netherlands Not Yet Recruiting

More Flevoziekenhuis trials in the Netherlands

Physical Exercise Prehabilitation Program in MEtabolic SuRgery Active, not recruiting
Chronic Fatigue in the Internal Medicine Outpatient Clinic: a Mixed-methods Quantitative and Qualitative Study Recruiting
HOspitalized Patients and Clinical flUid Status, Assessment Using Point Of Care UltraSound Recruiting

Other trials for the same condition

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity Recruiting
A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity Recruiting
Ketogenic Diet Prior to Bariatric Surgery Recruiting
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight Recruiting
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04852198 on ClinicalTrials.gov ↗ ← All trials in the Netherlands